Aged Diabetes Mellitus Type 2/complications/*drug therapy Disease Progression Disease-Free Survival Female Humans Hypoglycemic Agents/*therapeutic use Male Metformin/*therapeutic use Middle Aged Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Urinary Bladder Neoplasms/etiology/*mortality

Chemoradiotherapy/*methods Combined Modality Therapy Cystectomy/*adverse effects/methods Disease-Free Survival Female Humans Male Middle Aged Neoplasm Metastasis Robotic Surgical Procedures/*adverse effects/methods Treatment Outcome Urinary Bladder Neoplasms/diagnostic imaging/*therapy Bladder cancer Cystectomy Multi-modality treatment Port-site metastasis Rare complications

Estrogen Receptor alpha/metabolism Estrogen Receptor beta/metabolism Female Humans Immunohistochemistry/*methods Male Prognosis Receptors Androgen/metabolism Retrospective Studies Software Urinary Bladder Neoplasms/*metabolism/pathology

Adenocarcinoma/*etiology Carcinoma Squamous Cell/*etiology Carcinoma Transitional Cell/*etiology Case-Control Studies Cohort Studies Female Humans Male Neoplasm Recurrence Local Recurrence Regression Analysis Retrospective Studies Urinary Bladder Neoplasms/*etiology Urinary Tract Infections/*complications Bladder carcinoma Case–control studies Chronic urinary tract infection Meta-analysis

Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy

Cardiovascular Diseases/*etiology Cohort Studies Humans Hypoglycemic Agents/*adverse effects/pharmacology Non-alcoholic Fatty Liver Disease/*etiology/pathology Pioglitazone Prevalence Risk Thiazolidinediones/*adverse effects/pharmacology Urinary Bladder Neoplasms/epidemiology/*etiology/pathology Bladder cancer Cardiovascular disease Non-alcoholic steatohepatitis

Asian People/genetics Biomarkers Tumor/*blood/urine Cystoscopy/adverse effects Humans MicroRNAs/*blood Neoplasm Staging Nuclear Proteins/urine Odds Ratio ROC Curve Regression Analysis Sensitivity and Specificity Urinalysis/methods Urinary Bladder Neoplasms/*blood/diagnosis/*genetics/urine Bladder cancer Diagnosis Meta-analysis miRNA authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Cystectomy/*methods Female Humans Organ Sparing Treatments/*methods Postoperative Complications Sexual Dysfunction Physiological/*prevention & control Treatment Outcome Urinary Bladder/*pathology Urinary Bladder Neoplasms/physiopathology/*surgery Urinary Diversion/*methods Urinary Incontinence/*prevention & control #BladderCancer #blcsm radical cystectomy sexual function urinary bladder neoplasms urinary incontinence

*Adaptation Psychological Humans Quality of Life Survivors/*psychology Urinary Bladder Neoplasms/mortality/pathology/*psychology Bladder cancer Cystectomy Diagnosis Patients’ experience Treatment FUNDING: This work was funded by Yorkshire Cancer Research (grant number S388).

*Biomarkers Tumor Disease Progression Gene Expression Humans Matrix Metalloproteinases/*genetics/metabolism Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*genetics/metabolism/*mortality/pathology bladder cancer matrix metalloproteinases meta-analysis

Adjuvants Immunologic/*administration & dosage/adverse effects Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects BCG Vaccine Carcinoma in Situ/mortality/pathology/*therapy Combined Modality Therapy/adverse effects/methods Disease Progression Drug Administration Schedule Humans Interferon-alpha/*administration & dosage/adverse effects Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Withholding Treatment/statistics & numerical data

Arylamine N-Acetyltransferase/*genetics Genetic Predisposition to Disease Humans Isoenzymes/genetics Polymorphism Genetic Urinary Bladder Neoplasms/*genetics

Arylsulfotransferase/*genetics Case-Control Studies Genetic Association Studies Genetic Predisposition to Disease Genotype Humans NAD(P)H Dehydrogenase (Quinone)/*genetics Odds Ratio *Polymorphism Genetic Risk Factors Smoking/*adverse effects Urinary Bladder Neoplasms/enzymology/*genetics Nqo1 Sult1a1 meta-analysis polymorphisms smoking urinary bladder neoplasms

Age Factors Cystoscopy/*methods Cytodiagnosis Hematuria/*complications/*diagnosis Humans Predictive Value of Tests Sex Factors Smoking Time Factors Urinary Bladder Neoplasms/*complications/diagnosis/urine bladder cancer diagnosis haematuria timeliness urinary bladder neoplasm

Administration Intravesical Antibiotics Antineoplastic/*administration & dosage BCG Vaccine/administration & dosage Carcinoma in Situ/*drug therapy/mortality/pathology Carcinoma Transitional Cell/*drug therapy/mortality/pathology Disease Progression Electrochemotherapy/adverse effects/*methods Humans Mitomycin/*administration & dosage Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Biomarkers Tumor/genetics/urine Humans RNA/urine Sensitivity and Specificity Software Survivin/genetics/*urine Urinary Bladder Neoplasms/*diagnosis/*urine Bladder cancer Diagnosis Meta-analysis Survivin

Anemia/*complications Cystectomy/*methods Female Humans Male Preoperative Period Proportional Hazards Models Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*surgery Anemia Bladder cancer Hemoglobin Mortality Recurrence

Administration Intravesical BCG Vaccine/administration & dosage/*therapeutic use Chemotherapy Adjuvant Dose-Response Relationship Drug Drug Administration Schedule Humans Neoplasm Recurrence Local Prospective Studies Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/mortality/surgery

Diabetes Mellitus/diagnosis/*drug therapy/epidemiology Dose-Response Relationship Drug Humans Hypoglycemic Agents/*adverse effects Linear Models Multivariate Analysis Odds Ratio Pioglitazone Risk Assessment Risk Factors Thiazolidinediones/*adverse effects Time Factors Urinary Bladder Neoplasms/*chemically induced/diagnosis/epidemiology

Humans *Lymph Node Excision Lymphatic Metastasis Muscle Smooth/pathology Neoplasm Invasiveness Prognosis Urinary Bladder Neoplasms/pathology/*surgery Cáncer vesical con infiltración de la muscular Linfadenectomía Lymph node anatomical territory Lymphadenectomy Muscle invasive bladder cancer Oncological value Territorios anatómicos ganglionares Valor oncológico